Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash & Equivalents (2016 - 2025)

Kiora Pharmaceuticals' Cash & Equivalents history spans 11 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 129.41% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, up 129.41%, while the annual FY2025 figure was $8.7 million, 129.41% up from the prior year.
  • Cash & Equivalents reached $8.7 million in Q4 2025 per KPRX's latest filing, up from $5.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $31.3 million in Q1 2024 to a low of $1.0 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $6.7 million, with a median of $5.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 811.9% in 2024, then tumbled 87.85% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $7.9 million in 2021, then crashed by 38.6% to $4.9 million in 2022, then plummeted by 49.31% to $2.5 million in 2023, then surged by 54.23% to $3.8 million in 2024, then soared by 129.41% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Cash & Equivalents are $8.7 million (Q4 2025), $5.5 million (Q3 2025), and $1.0 million (Q2 2025).